ArticleInternational journal of pharmaceutics2022
Microneedle and iontophoresis mediated delivery of methotrexate into and across healthy and psoriatic skin.
Article in International journal of pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Driving Drugs Deeper: Force-Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Exploring the role of neuro-immune modulation for psoriasis management: a narrative review of existing evidence and future therapies.Brain, behavior, & immunity - health · 2026Review
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Recent Advancement in Drug Delivery Systems for the Treatment of Rheumatoid Arthritis.Current drug discovery technologies · 2026Review
- Development of buspirone hydrochloride-loaded long-acting microneedles for management of anxiety disorders.Drug delivery and translational research · 2025Article
- Iontophoresis and electroporation-assisted microneedles: advancements and therapeutic potentials in transdermal drug delivery.Drug delivery and translational research · 2025Review
- A complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Recent advances in iontophoresis-assisted microneedle devices for transdermal biosensing and drug delivery.Materials today. Bio · 2025Review
- Microneedle-Mediated Treatment of Obesity.Pharmaceutics · 2025Review
- Harnessing Ultrasonic Technologies to TreatMolecules (Basel, Switzerland) · 2025Review
- Microneedles as transdermal drug delivery system for enhancing skin disease treatment.Acta pharmaceutica Sinica. B · 2024Review
- Enhancing topical delivery of ISRIB: Optimizing cream formulations with chemical enhancers and pH adjustment.International journal of pharmaceutics · 2024Article
- Polymeric Microneedles Enhance Transdermal Delivery of Therapeutics.Pharmaceutics · 2024Article
- Transcutaneous Delivery of Dexamethasone Sodium Phosphate Via Microneedle-Assisted Iontophoretic Enhancement - A Potential Therapeutic Option for Inflammatory Disorders.Pharmaceutical research · 2024Article
- Microneedle-mediated transdermal delivery of N-acetyl cysteine as a potential antidote for lewisite injury.International journal of pharmaceutics · 2023Article
- Iontophoresis-Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program that Stimulates Transcutaneous Vaccination for Cancer Immunotherapy.Small science · 2023Article
- Enhanced Transdermal Delivery of N-Acetylcysteine and 4-Phenylbutyric Acid for Potential Use as Antidotes to Lewisite.AAPS PharmSciTech · 2023Article
- Modeling of Microneedle Arrays in Transdermal Drug Delivery Applications.Pharmaceutics · 2023Article
- Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis.Drug delivery · 2022Article
- Utilization of ex vivo tissue model to study skin regeneration following microneedle stimuli.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Psoriasis is a condition of the skin which involves scales, dry patches, and inflammation. Methotrexate (logP: -1.8, MW:454.44 g/mol) is administered orally or intravenously to treat psoriasis. The first-pass metabolism and systemic toxicity can be avoided by administration via skin. Topical and transdermal delivery of methotrexate using iontophoresis and microneedles, alone and in combination was investigated using full-thickness healthy human skin. It is also equally relevant to evaluate the delivery into and across damaged/diseased skin. Hence, this study investigated the delivery of methotrexate using ex vivo healthy and psoriatic human skin to understand the effect of skin disease condition on delivery of methotrexate via skin. A lower resistance and a higher TEWL for psoriatic skin indicated damaged barrier function, while histology studies indicated epithelial hyperproliferation and elongated rete ridges. Using the optimized iontophoretic parameters, there was no significant difference in receptor delivery for psoriatic skin (39.51 ± 4.45 µg/sq.cm) as compared to healthy skin (43.15 ± 0.83 µg/sq.cm). However, methotrexate delivery into psoriatic skin (126.23 ± 24.65 µg/sq.cm) was significantly higher as compared to healthy skin (12.02 ± 4.89 µg/sq.cm). Thus, significantly higher total delivery was observed from psoriatic skin than healthy skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.